Tavaborole is a boron-based pharmaceutical agent. It has broad-spectrum oxaborole antifungal activity. Due to its low molecular weight, it facilitates maximal nail plate penetration than its predecessors.
Synonyms: 1,3-Dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole; 5-Fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole; AN-2690; AN2690
Molecular Formula: C7H6BFO2
Molecular Weight: 151.93
Linear Structural Formula: C7H6BFO2
Purity: >=95% (HPLC)
Storage: -20C
Biochem Physiol Actions: Tavaborole (AN2690) is a potent antifungal that targets the post-transfer editing site of leucyl-tRNA synthetase (LeuRS). Tavaborole forms a covalent adduct with the 3' adenosine of tRNA(leu) at the editing site of fungal, but not bacterial LeuRS, locking the enzyme in an inactive conformation. Tavaborole was recently approved for the treatment of onychomycosis of the toenail in adults.